Investors took off exposure to Exact Sciences (NASDAQ:EXAS) in September ahead of a key update to colon cancer screening and that decision appears to have been the right one given that guidelines announced this month failed to include Exact Sciences' Cologuard.
In the following slideshow, you'll learn why this update to guidelines was important for Exact Sciences and the risks that its investors continue to face.
